Table 1.
The Clinical Characteristic of 80 Patients with Progressive Disease
| Characteristic | Treatment group (n) | Control group (n) | p |
|---|---|---|---|
| Age (y) | |||
| <40 | 20 | 20 | – |
| ≥40 | 20 | 20 | |
| Pathology type | |||
| Invasive ductal carcinoma | 39 | 37 | 0.304 |
| Mucinous adenocarcinoma | 1 | 3 | |
| ER/PR status | |||
| ER(+) and PR(+) | 37 | 35 | 0.456 |
| ER(+) and/or PR(+) | 3 | 5 | |
| Her-2 | |||
| Positive | 10 | 12 | 0.617 |
| Negative | 30 | 28 | |
| Site of disease progression | |||
| Chest wall | 6 | 5 | – |
| Regional lymph nodes | 8 | 9 | |
| Chest wall and regional lymph nodes | 1 | 1 | |
| Bone | 10 | 9 | |
| Liver | 2 | 1 | |
| Lung | 3 | 4 | |
| Chest wall and bone | 3 | 4 | |
| Regional lymph nodes and bone | 6 | 6 | |
| Chest wall, regional lymph nodes, and bone | 1 | 1 | |
ER, estrogen receptor; PR, progesterone receptor; Her-2, human epidermal growth factor receptor 2.